Rezolute(RZLT) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation Open-label arm (infant participants < 1 year old) of the sunRIZE study has been reviewed by a Data Monitoring Committee (DMC); target drug concentrations were safely reached at tested doses and infants are approved for enrollment into the doub ...